Company intelligence / Profile preview

Surface Oncology

Cambridge, Massachusetts, United Statesx.com ↗

Ownership: Public · SURF
Employees: ~60
Development stage: Phase 2

Overview

Surface Oncology developed next-generation immuno-oncology antibody therapies targeting the tumor microenvironment. Its lead program SRF388 showed a 27% objective response rate and a 65% disease control rate in early data for first-line advanced hepatocellular carcinoma when combined with atezolizumab and bevacizumab. Both SRF388 and SRF114 demonstrated acceptable safety profiles in clinical studies. The company also had outlicensed programs partnered with Novartis and GlaxoSmithKline.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodies (mAbs)
Industry: Biotech

Drug pipeline

4 assets

SRF388

Phase 2

Indications: Non-small cell lung cancer, Hepatocellular carcinoma

3 more assets in the full pipeline.

Request access →

Partnerships

Novartis (CD73 program/NZV930)GlaxoSmithKline/GSK (PVRIG/CD112R program/GSK4381562)

Financials

Market cap: $65.1M
Total revenue: $0
Enterprise value: $18.3M

Beyond the preview

Go deeper on Surface Oncology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Surface Oncology.

Explore the full profile